Press Release
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation
- The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication[1]
- The European Commission decision for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) is expected later this year.
CASTRES, France, July 26, 2024 /PRNewswire/ — Pierre Fabre Laboratories announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation. The positive opinion will now be submitted to the European Commission (EC) with a decision on EU marketing authorisation (MA) expected later this year.
Eric Ducournau, Chief Executive Officer, Pierre Fabre Laboratories said: "The positive CHMP opinion marks a pivotal step in our commitment to delivering an additional effective targeted treatment option for patients with advanced NSCLC with a BRAFV600E mutation, who at present have limited treatment options. We look forward to the European Commission’s decision to make BRAFTOVI® + MEKTOVI® available to non-small cell lung cancer patients in Europe."
The CHMP positive opinion is supported by data from the global, open-label, multicentre, non-randomised Phase II PHAROS trial, which included 98 patients from 56 study centres across 5 countries.[1]
At primary analysis (cut-off date: September 22, 2022), the primary endpoint of the trial (objective response rate [ORR] determined by independent radiology review [IRR]) was met. The PHAROS trial showed that in patients with advanced NSCLC with a BRAFV600E mutation, BRAFTOVI® and MEKTOVI® provided a meaningful clinical benefit with an ORR of 75% (95% CI: 62, 85) in treatment naïve patients (n=59), with 59% of them maintaining their response for at least 12 months. For those patients who had received prior therapy (n=39), the ORR was 46% (95% CI: 30, 63), with 33% maintaining their response for at least 12 months.[1]
CONTACT: Laurence MARCHAL laurence.marchal@pierre-fabre.com
The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of ThailandChina.
Corporate
Will you still have an office in the post Covid-19 world?
Businesses waste vast resources paying leases for real estate they simply don’t need. Flexible working spaces are a vital way of ensuring that no longer happens.
HONG KONG – (ACN Newswire) – While the pandemic has led many to believe remote work will become the norm, concerns about lagging creativity and loneliness show that there is still a role for the office in a post Covid-19 world, according to The Executive Centre (TEC).
(more…)Markets
Tiger Trade Launches SGX Trading, Meeting Demand from Asian Investors
Access to the Singapore Exchange (SGX) adds to Tiger Brokers’ current menu of stock exchanges, such as the New York Stock Exchange (NYSE) and the Nasdaq Stock Market (NASDAQ), the world’s two largest stock exchanges, as well as the Hong Kong Stock Exchange (HKEX).
SINGAPORE (ACN Newswire) – Tiger Trade, a one-stop mobile and online trading application by Tiger Brokers, has launched access to the Singapore Exchange (SGX).
(more…)Health
APRIL International Care opens up TeleHEALTH service to address Coronavirus worries
The TeleHEALTH service means policyholders do not have to leave their home or workplace to “see” a doctor, with a consultation happening directly over the phone
Hong Kong February 10, 2020 – APRIL International Care has opened up its TeleHEALTH service to all individual and group clients across its Asian region to provide support for clients during the current Coronavirus outbreak.
(more…)- McKinsey Reduces Workforce by 500 in Overhaul of China Operations – WSJ
- India’s Setback in Bangladesh May Not Equate to China’s Advantage
- Why China is seeking greater presence in Africa – the strategy behind its financial deals
- Trends in China’s Outbound Investment: Key Sources, Destinations, and Sectors
- This Chinese EV Manufacturer is Ready to Compete with Elon Musk in China
- China’s probe of Canadian canola will put both exports and farmers in jeopardy
